Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-25

No results posted yet for this study

Summary

combination deucravacitinib and enstilar foam

Conditions

Interventions

DRUG

Enstilar

Add on Enstilar

DRUG

Deucravacitinib

6mg QD

Sponsors & Collaborators

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-06
Primary Completion
2023-11-13
Completion
2023-11-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06329258 on ClinicalTrials.gov